Partovet

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Partovet

Property Description
Active ingredient Oxytocin (Nonapeptide Hormone)
Form Injectable Solution (Sterile Aqueous Liquid)
Pharmacological class Oxytocic Agent, Uterotonic Agent
General purpose Stimulates smooth muscle for contractions and milk ejection
Origin Synthetic, structurally identical to endogenous hormone

Partovet is a veterinary medicinal product defined by its single active substance, Oxytocin, and is classified therapeutically as an Oxytocic Agent. Oxytocin is recognized for its inclusion on the List of Essential Medicines due to its uterotonic properties and its specific pharmacological action.

Identity and Pharmacological Classification

Partovet belongs to the pharmacological class of Oxytocic Agents, compounds recognized for stimulating smooth muscle contractions. The active ingredient, Oxytocin, is a hormone synthesized in the hypothalamus. The final preparation, Partovet, is manufactured as an Injectable Solution—a sterile, clear aqueous liquid—designed for parenteral administration in target species. The nature of the Oxytocin preparation supports a consistent pharmacological effect and physiological responses when administered.

Is Partovet a Natural or Synthetic Hormone?

The formulation utilizes synthetic Oxytocin, a nonapeptide hormone chemically and structurally identical to the natural, endogenous form. This synthetic origin allows for a standardized and purified product for therapeutic action. As a single-agent product (monotherapy), Partovet contains the active hormone dissolved in an aqueous base, such as water for injections. This specific formulation is designed for rapid systemic availability.

General Purpose: What Does Partovet Fundamentally Do?

The general purpose of Partovet stems from its ability to stimulate the oxytocin receptors found on the smooth musculature of the uterus and the myoepithelial cells of the mammary gland. This action is associated with the completion of reproductive processes and the activation of the milk ejection reflex. These actions support reproductive and lactational functions, utilizing the hormone's contractile properties to facilitate physiological processes in the animal.

Regulatory References

  1. World Health Organization
  2. WHO Essential Medicines

What side effects are possible with Partovet?

Possible Side Effects and Safety Information

Partovet’s safety profile, based on official regulatory documents, details potential adverse reactions by frequency and the body system affected.


Adverse Reaction Scope

Category Official Regulatory Documentation
Frequency Classification Common (1/100): Nausea, Vomiting, Headache. Uncommon (1/1,000): Cardiac Arrhythmia, Bradycardia. Rare (1/10,000): Anaphylactic reactions, Disseminated Intravascular Coagulation (DIC).
System-Organ Classes Adverse effects are documented primarily in the Cardiac, Vascular, Gastrointestinal, and Nervous System Disorders categories.
Serious Adverse Reactions Officially documented serious, low-incidence events include DIC, Anaphylaxis, Subarachnoid Hemorrhage, and Myocardial Ischemia (frequency not precisely known in all labels).
Safety-Related Restrictions Use is strictly constrained by a known hypersensitivity to the active substance, Oxytocin.

Regulatory Safety Context

The most profound cardiovascular effects, such as acute severe hypotension and tachycardia, are specifically linked to the rate of administration, with adverse events observed immediately following rapid injection. Regulatory labeling also includes special safety considerations for individuals with pre-existing cardiovascular conditions due to the drug's known vascular effects. Furthermore, the active substance possesses a slight antidiuretic property, leading to official warnings regarding the potential for water intoxication when high doses are administered with large volumes of fluid.


Resulting Safety Structure

The official safety information structures the understanding of risks by categorizing adverse events, highlighting both common reactions and rare but serious systemic effects. This framework emphasizes that significant safety considerations are related to the administration context and pre-existing patient conditions, establishing the documented constraints on its use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Partovet (Oxytocin) overdose is defined by two primary clinical concerns: uncontrolled uterine hyperactivity and severe systemic water intoxication.

Documented Manifestations and Severe Outcomes: Overdosage is generally evidenced by uterine hyperstimulation—contractions that are too frequent, strong (hypertonic), or prolonged (tetanic), often with an elevated resting uterine tone. Unmanaged hyperactivity can lead to uterine rupture, postpartum hemorrhage, and severe fetal distress (e.g., bradycardia, variable deceleration) that may result in permanent CNS damage or fetal death. Due to the inherent antidiuretic property of Oxytocin, high-dose, prolonged intravenous administration with excessive fluid volumes risks water intoxication. Manifestations of this include headache, lethargy, and severe neurological events like convulsions or coma, which are documented causes of maternal death.

Mandatory Emergency Action: Management consists of symptomatic and supportive therapy, as no specific antidote is officially documented. The required immediate action is the discontinuation of the Oxytocin infusion upon the first sign of hyperstimulation or fetal distress. Emergency medical services must be contacted immediately if severe symptoms such as convulsions, coma, or signs of life-threatening water intoxication are observed. All patients receiving intravenous Oxytocin must be under continuous observation for early detection of overdosage.

Therapeutic Uses of Partovet

What Partovet Treats: Main Uses and Benefits

Partovet is applied across domains where additional symptomatic support is needed, addressing symptoms that interfere with daily functioning. Its use is relevant in clinical settings that involve acute or unstable symptom patterns, which is consistent with its indications. The active agent's indications include use in certain acute clinical procedures. Partovet is commonly used across conditions characterized by periods of heightened symptoms or recurrent manifestations, which is generally relevant when short-term symptomatic assistance is needed.

The medication helps address symptom clusters that may appear suddenly and create noticeable functional strain. It is intended to support the patient during difficult episodes by easing distress. It assists with maintaining functional stability and contributes to easing the overall symptom load during symptomatic phases.


Quick Fact: Relief for Acute Symptom Fluctuation

Eligibility and Restrictions for Use

The eligibility for Partovet (Oxytocin injection, veterinary medicinal product) is strictly defined by regulatory guidelines concerning the animal's reproductive status and physical health. The medicine is officially indicated for administration in specific target species, including cattle, horses, pigs, sheep, goats, dogs, and cats. Its use is formally restricted to the mature breeding stage, specifically for promoting parturition (delivery) and aiding milk let-down during lactation.

When Use is Prohibited (Contraindications)

Regulatory documents state that Partovet must not be used in animals exhibiting certain conditions. Absolute prohibitions include any evidence of obstructive dystocia (physical blockages to birth) or the presence of an unopened cervix, as these prevent safe delivery and risk uterine rupture. Use is also strictly contraindicated for any animal with a documented hypersensitivity to the active ingredient, Oxytocin.

Restrictions and Caution

Use is not recommended or requires special caution in populations presenting with pre-existing organ issues, specifically Impaired Cardiac Function or Impaired Renal Function. The regulatory profile contains no explicit limitations regarding geriatric or pediatric age groups, as the use is limited to reproductively mature animals.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for this medication focuses primarily on pharmacodynamic interactions, which involve combined effects on body systems rather than metabolic pathway interference. The labels document several classes of medicinal products requiring specific precautions or restrictions.

Documented Interaction Restrictions

  • Prostaglandins and Analogues: Co-administration is classified as a restricted or contraindicated combination due to the officially documented risk of potentiating uterotonic effects, which can lead to uterine hyperstimulation. A mandatory timing rule requires administration to be separated from vaginal prostaglandins by at least six hours.
  • Cardiovascular Agents: Co-administration with sympathomimetic vasoconstrictors has been associated with reports of severe hypertension, particularly when administered following caudal block anesthesia. The use of certain inhalation anesthetics may also modify cardiovascular effects, potentially causing hypotension or abnormal heart rhythms.
  • Fluid Management: The product possesses an inherent antidiuretic property. When administered continuously with large volumes of non-electrolyte intravenous fluid, this effect creates a documented risk of fluid accumulation, leading to severe water intoxication and hyponatremia.
  • Other Pharmacodynamic Effects: Interactions are also documented for medicinal products known to prolong the QTc interval, which may increase the arrhythmogenic potential. The medication may also enhance the action of neuromuscular blocking agents such as succinylcholine.

The overall interaction structure is defined by the necessity to manage cumulative contractile effects and fluid-electrolyte balance risks documented in the product's official labeling.

Mechanism of Action

Partovet acts by engaging specific molecular and physiological mechanisms within targeted biological systems. Its effects are channeled through distinct mechanistic domains, achieving focused modulation of specific signaling pathways.


Modulating Receptor-Mediated Signaling

This domain involves Partovet’s interaction with specific cell-surface receptors to either initiate or suppress downstream signaling sequences. By engaging mechanisms that regulate these receptor-ligand interactions, the compound modifies early molecular steps that govern the resulting systemic physiological outcomes, such as attenuating specific signaling responses.


Regulating Key Pathway Activity

Partovet acts within systems where targeted pathway adjustment is required, influencing cascades where specific transmitters or mediators dominate. This mechanism supports the regulation of processes driven by distinct signaling patterns, reducing the magnitude of mediator-driven activity and adjusting pathway activity patterns.


Influencing Feedback Regulation

This domain focuses on the compound's role in engaging mechanisms that influence feedback regulation within signaling pathways. Partovet modifies the molecular steps that shape how pathways respond to internal signals, ultimately leading to predictable physiological adjustments contributing to pathway activity maintenance.

Dosage and Administration Information

How Partovet is Used: Administration Guidelines

The administration of Partovet, an injectable solution, is intended for use by or on the order of a licensed veterinarian. The product is a short-acting preparation and is administered via parenteral injection. The recognized routes include intramuscular (IM), subcutaneous (SC), and intravenous (IV) injection.

The standard administration protocol depends on both the animal species (e.g., Cow, Sow, Queen) and the clinical objective (obstetrics or milk let-down), with the required dose measured in International Units (IU). A low initial dosage is generally utilized for all routes of administration. The maximum dosage is typically reserved for use in post-parturient animals (after delivery), and repeat administration is considered permissible only after a specified interval, often set at approximately 30 minutes, if required.

Specific preparation is necessary when the intravenous route is chosen. IV doses are administered slowly and often involve dilution (e.g., 1 in 10) with Water for Injections Ph. Eur. If the IV route is utilized, the dose is typically reduced to one-quarter of the corresponding intramuscular dose for that species. The injection is not given simultaneously by more than one route. The medication is intended for short-term, acute use rather than long-term or regular administration.

Recent Clinical Evidence

Partovet: Recent Clinical Evidence


Evidence for use in Labor Facilitation (Uterine Inertia / Dystocia)

The research base for the active substance in Partovet was evaluated in studies exploring uterine function during labor challenges, such as conditions characterized by weak or absent contractions. Research explored this use through controlled clinical studies, monitoring physiological outcomes like the frequency and intensity of contractions and the time to delivery completion. Studies reported measurements consistent with the substance's known pharmacological class.

The regulatory assessments classify the substance as an established pharmacological agent, yet research suggests a key limitation: successful administration may be reliant on the prior correction of any malpositioning of the fetus. Furthermore, there is limited information for long-term outcomes for future reproductive cycles.

Evidence for use in Post-Partum Uterine Recovery

Research was evaluated in the context of post-delivery uterine recovery. The evidence base here largely relies on long-established clinical knowledge and regulatory assessments. Studies reported measurements of the rate of uterine involution and the physiological processes associated with the expulsion of post-delivery materials.

Due to the long-standing nature of this use, comparative evidence is lacking in the form of new, large-scale controlled trials. Follow-up durations were limited, characterizing only the immediate post-partum recovery period, and there is limited information for long-term outcomes related to uterine health after the acute period.

Evidence for use in Stimulating Milk Ejection

The substance was studied for outcomes related to the milk ejection reflex. Research explored its role through controlled protocols and challenge tests, monitoring the induction of the reflex and the efficiency of milk evacuation in lactating species. Crucially, results apply only to the populations studied and do not determine whether the substance can increase overall milk production.

Research also examined observations in some studies reporting patterns that repeated use over time may be associated with subsequent changes in the studied animal's capacity for spontaneous milk ejection after the study period.

Evidence in Various Animal Populations

Research was evaluated in multiple domestic and livestock species, including cows, horses, sows, goats, dogs, and cats. The studies explored how the substance was observed across these different animal groups, which informs the evidence for its regulated use in various species.

Long-term Studies and Follow-up

Research explored outcomes over defined short-term intervals. Long-term effects on animal health or the durability of the initial response are not fully established. Follow-up durations were limited in most primary research.

What Research Gaps and Uncertainties Remain

Evidence quality varies across studies, and some findings were mixed regarding physiological response in managing labor complications. Data for certain groups remain insufficient, particularly concerning long-term effects on reproductive performance. Overall, research is ongoing to better characterize these specific limitations.

Frequently Asked Questions (FAQ)

Common questions about Partovet (FAQ)

Q: Is Partovet a brand-new drug, or has it been around for a while?

A: The active ingredient in Partovet, Oxytocin, is a naturally occurring hormone found in the body. The medication itself is a synthetic version that is chemically identical to the natural hormone. It has been classified as an established pharmacological agent and has been in medical use for many decades.

Q: What is the typical timeframe before Partovet reaches its full effect?

A: Partovet is a short-acting preparation designed for rapid effect. Official pharmacokinetic data indicates that following intravenous administration, the effects typically begin within approximately one minute. When administered intramuscularly, the effects usually start within three to five minutes.

Q: How quickly does Partovet leave the system after stopping use?

A: The substance is rapidly cleared from the bloodstream after its acute use. Pharmacokinetic data indicates that following intravenous administration, the half-life (the time it takes for half the medication to be cleared) is approximately three to five minutes.

Q: Is Partovet considered a controlled substance?

A: According to official scheduling classifications, Partovet (Oxytocin) is not classified as a controlled substance under the Federal Controlled Substances Act or similar international schedules.

Q: Do you need special blood tests while taking Partovet?

A: Official product information emphasizes that monitoring of the patient's condition is part of the administration protocol. If Partovet is administered continuously in high doses with large volumes of intravenous fluid, regulatory documents state that monitoring of electrolytes is necessary. This precaution is documented due to the drug’s inherent antidiuretic property and the risk of water intoxication.

Q: What happens if Partovet expires?

A: The World Health Organization warns that the active substance is sensitive to temperature and time. If the product has expired or was improperly stored, the medication is likely to rapidly degrade and lose its efficacy and potency. This can result in a product that may not meet its required standards for efficacy and potency.

Q: Is it common to feel tired when you first start taking Partovet?

A: General fatigue is not listed as a common side effect in the official safety documents. However, these documents do mention that symptoms like lethargy and drowsiness are documented signs of a rare, serious complication called water intoxication, which is linked to high doses given with large amounts of fluid.

Q: How does Partovet affect the liver?

A: The active substance, Oxytocin, is primarily metabolized (broken down) by the liver and kidneys. While this indicates the liver is involved in clearing the substance from the system, the main safety profile officially documents adverse effects in the Cardiac, Vascular, GI, and Nervous systems, but not the liver as a primary site for adverse reactions.

Q: Is Partovet known to cause mood swings or emotional changes?

A: The documented safety profile does not list general mood swings as an adverse reaction. However, rare, serious reactions linked to water intoxication (which occurs with excessive fluid and high doses) can include severe neurological effects such as confusion and hallucinations.

Q: Is Partovet safe to take with common cold or flu medicines?

A: The official interaction profile states that co-administration with sympathomimetic vasoconstrictors is restricted due to a documented risk of severe hypertension. Because some common cold and flu remedies contain these ingredients, official product information suggests caution regarding co-administration with products containing these restricted ingredients.

Q: Are there any specific foods or drinks I should avoid while taking Partovet?

A: Regulatory documents focus mainly on the drug’s interactions with other medicinal products and its effect on fluid balance. They do not typically list specific restrictions for common foods or non-alcoholic drinks. For guidance tailored to the patient’s specific use, the product information recommends checking with a veterinary professional.

Q: Is it possible to develop a tolerance to Partovet over time?

A: Official product documents define this medication for short-term, acute use and state it is not permitted for long-term administration. Because of its strictly limited use, regulatory documents do not typically address the topic of long-term pharmacological tolerance or dependence.

Q: Does Partovet affect fertility in men or women?

A: The research supporting this medication focuses on its acute use in reproductive processes. Official research assessments currently indicate limited information for long-term outcomes for future reproductive cycles following its use for labor facilitation.

Q: What does the research say about Partovet's effectiveness compared to no treatment?

A: Studies evaluating the active substance reported physiological measurements consistent with its known pharmacological class (Oxytocic Agent). This evidence supports its established effects of stimulating uterine smooth muscle contractions and the milk ejection reflex.

Q: Does Partovet have a generic version available?

A: The active ingredient, Oxytocin, is itself the non-proprietary or generic name for this drug substance. It is manufactured and commonly marketed by various companies under different brand names, and the availability of a specific generic product can vary by region.

How should Partovet be stored and disposed of?

How to Store and Dispose of Partovet?

Partovet (Oxytocin Injection) must be stored under specific, mandated conditions to protect its stability.

Item Official Regulatory Statement
Storage Temperature Store at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F).
Protection Do not freeze the solution, and protect the product from freezing.
Handling Visually inspect the solution for particulate matter or discoloration before administration; do not use if observed.
Container Store in the original container with the cap securely in place.

For safety, the product must be stored out of the sight and reach of children.

Disposal Requirements:

Disposal of unused or expired Partovet must follow local regulatory requirements. The medication should not be disposed of via wastewater or household waste to prevent environmental contamination. Consult local authorities or a pharmacist for instructions on proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Partovet found in:

A-Z Index: